Pfizer Inc.
NEISSERIA MENINGITIDIS COMPOSITION AND METHODS THEREOF

Last updated:

Abstract:

In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

Status:
Application
Type:

Utility

Filling date:

30 Sep 2020

Issue date:

28 Jan 2021